A Preliminary Evaluation on the Antifungal Efficacy of VT-1161 against Persister Candida albicans Cells in Vulvovaginal Candidiasis
Persister cells are a small fraction of the microbial population that survive lethal concentrations of antimicrobial agents. causes vaginal candidiasis, including recurrent vulvovaginal candidiasis, and may survive common antifungal treatments. The triazole VT-1161 is an antifungal agent that specif...
Saved in:
Published in | Biomedicines Vol. 12; no. 2; p. 389 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
07.02.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Persister cells are a small fraction of the microbial population that survive lethal concentrations of antimicrobial agents.
causes vaginal candidiasis, including recurrent vulvovaginal candidiasis, and may survive common antifungal treatments. The triazole VT-1161 is an antifungal agent that specifically targets fungal CYP51, as opposed to the human CYP enzyme. This work illustrates a new role of VT-1161 in eradicating the biofilm created from the persister cells of a primary biofilm of a clinical vaginal isolate of
. Antifungal activity was determined by the minimum inhibitory concentration (MIC), and the primary biofilm was treated with amphotericin B to obtain persister cells that were able to form a new biofilm. Results obtained using the new azole VT-1161 showed that VT-1161 not only eradicated a secondary biofilm formed from the persister-derived biofilm and counteracted the adhesion of
in vitro to human cells but also ameliorated
-induced infection in vivo in
larvae, suggesting that it could be proposed as an alternative therapeutic strategy for the treatment of recurrent candidiasis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2227-9059 2227-9059 |
DOI: | 10.3390/biomedicines12020389 |